Generic drug sponsors would receive more inactive ingredient information about their reference products faster thanks to a provision in the House US Food and Drug Administration user fee reauthorization bill.
The change is intended to speed generic entry, but the brand industry already is concerned, which could endanger its survival...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?